NCT05421429View on ClinicalTrials.gov

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

January 17, 2024

Study Completion Date

January 17, 2024

Conditions
Hemophilia
Interventions
BIOLOGICAL

KN057 doseⅠ

KN057 subcutaneous (SC) injection

BIOLOGICAL

KN057 dose Ⅱ

KN057 SC injection

BIOLOGICAL

KN057 dose Ⅲ

KN057 SC injection

Trial Locations (2)

300020

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

stitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Suzhou Alphamab Co., Ltd.

INDUSTRY